Drugs & Pharmacology 
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 28.
We Can't Deny It: We Are Leaders. . . . .
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Tags: New York State Council of Health-system Pharmacists Section Source Type: research
Cryptogenic Organizing Pneumonia During Adjuvant Chemotherapy With Oxaliplatin, 5-Fluorouracil, and Leucovorin (FOLFOX) for Colon Cancer
We describe a case of cryptogenic organizing pneumonia (COP) occurring in a 78-year-old woman after receiving 2 cycles of modified FOLFOX6 as adjuvant chemotherapy for treatment of resected nonmetastatic colon cancer. This patient presented with respiratory symptoms including cough with scant clear sputum and wheezing on day 10 of the second cycle of mFOLFOX6. Despite therapy with systemic antibiotics and supplemental oxygen, she had a steady and relentless progression of her respiratory symptoms and status, with chest radiographs revealing progressive bilateral pulmonary infiltrates. Further chest radiograph evaluation de...
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Shogbon, A. O., Hap, J., Dretler, R., Dalvi, A. G. Tags: Adverse Drug Events Source Type: research
Graves' Hyperthyroidism-Induced Psychosis Treated With Aripiprazole--A Case Report
We report the first known case on the use of aripriprazole to treat Graves’ hyperthyroidism-induced psychosis. Further studies examining the long-term effects and appropriate dose and duration of aripiprazole in this patient population are needed.
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Macedo, L. R., Marino, J., Bradshaw, B., Henry, J. Tags: Adverse Drug Events Source Type: research
Benign Prostatic Hyperplasia: Implications for Pharmacologic Treatment and Perioperative Care
This review provides an update on the treatment of benign prostatic hyperplasia and the pharmacologic considerations for perioperative care. By age 85 years, approximately 90% of men have prostate histologic characteristics consistent with benign prostatic hyperplasia. Pharmacologic treatment with an alpha1 receptor antagonist may reduce symptoms and, when given in combination with a 5-alpha-reductase inhibitor, may decrease the risk of urinary retention and the need for surgical intervention. Transurethral resection of the prostate has been the historical standard when surgical intervention is indicated. However, recent e...
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Leedahl, D. D., Vo, P. H., Maxson, P. M., Lovely, J. K. Tags: Review Articles Source Type: research
Contemporary Anticoagulation Reversal: Focus on Direct Thrombin Inhibitors and Factor Xa Inhibitors
Several oral direct thrombin inhibitors (DTIs) and factor Xa (FXa) inhibitors have recent Food and Drug Administration approval or are under investigation in late-stage clinical trials for the prevention and treatment of thromboembolic events. Rapid reversal of anticoagulation is typically recommended in patients with severe or life-threatening bleeding and in patients requiring surgery or invasive procedures. However, no antidote exists for DTIs or FXa inhibitors though replacement of coagulation factors using clotting factor concentrates is routinely considered in some clinical scenarios. Clotting factor concentrates ava...
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Mancl, E. E., Crawford, A. N., Voils, S. A. Tags: Review Articles Source Type: research
Awareness and Perceptions of Vermont's Prescribed Product Gift Ban and Disclosure Law by Prescribers and Pharmacists
Conclusions:
A high proportion of Vermont providers are unaware of the current law. Most agreed or had no strong opinions about the requirements; however, at least a quarter disagreed with banning small gifts and meals. Having any interaction with pharmaceutical representatives changed how providers perceived the requirements. These data may be useful for other states considering similar laws.
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Kennedy, A. G., Possidente, C. J., Pinckney, R. G. Tags: Pharmacy Law Source Type: research
The Development of a Patient Care Center in a Supermarket Chain Pharmacy
Conclusions:
Establishing a patient care center in a supermarket pharmacy provides important care for patients and valuable learning experiences for student pharmacists. The collaborative efforts of both Wayne State University and Kroger Pharmacy demonstrate commitment to providing clinical care to patients and strong clinical community practice experiences for students. Future goals include creating more clinical services in the community and practice experiences for students.
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Pattin, A., Szyskowski, J. Tags: Research Article Source Type: research
Asthma Education in the Student Laboratory
The Integrated Pharmacy Skills Laboratory (IPSL) at South University School of Pharmacy is dedicated to providing future pharmacists with the necessary knowledge and skills to care for asthma patients. Asthma is a chronic respiratory disorder that is characterized by airway inflammation, hyper responsive airways, and bronchoconstriction. It affects more than 30 million people and accounts for $30 billion in health care costs. Therefore, it is vital for our students to be educated in asthma management including medications and devices to improve patient outcomes. Students, as future pharmacist, learn to manage asthma patien...
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Thurmon, T. B., Schwartz, L. L., Jervis, K. P. Tags: Theme Articles Source Type: research
Combination Pharmacotherapy in the Treatment of Pulmonary Arterial Hypertension: Continuing Education Article
Pulmonary arterial hypertension (PAH) is a disorder of the small pulmonary arteries characterized by progressive fibrotic and proliferative changes that result in an increased pulmonary vascular resistance. It is a progressive and debilitating disease that leads to right ventricular dysfunction, impairment in activity tolerance and eventually right-sided heart failure, and premature death. The treatment goals for PAH include improvement in symptoms, improvement in functional class and exercise class, decreased morbidity, and preventing mortality. Combination therapy in the treatment of PAH is an emerging therapeutic option...
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Tackett, K. L., Stajich, G. V. Tags: Theme Articles Source Type: research
Complementary Therapies in Cystic Fibrosis: Nutritional Supplements and Herbal Products
This article offers an overview of the most common complementary therapies in cystic fibrosis such as vitamin A, vitamin C, vitamin E, zinc, omega 3 fatty acids, docosahexaenoic acid (DHA), garlic, ginseng, and curcumin.
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Braga, S. F. F., Almgren, M. M. Tags: Theme Articles Source Type: research
Pharmacotherapy of Lung Transplantation: An Overview
Lung transplantation has become a viable treatment therapy for end-stage lung disease patients. The most common etiologies of end-stage lung disease, which can require a transplant are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and pulmonary fibrosis (PF). Listing criteria are institution and program specific. Approximately 1500 lung transplants were performed in 2008; and at 5 years post transplant, one-half are expected to survive. The surgery itself is associated with various complications, including surgical, infectious, and mechanical. Immu...
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Thompson, M. L., Flynn, J. D., Clifford, T. M. Tags: Theme Articles Source Type: research
Introduction to Pulmonary Medicine: Part II
Source: Journal of Pharmacy Practice - February 15, 2013 Category: Drugs & Pharmacology Authors: Tackett, K. L., McKeever, A. L. Tags: Theme Articles Source Type: research
Application of Physicochemical Properties and Process Parameters in the Development of a Neural Network Model for Prediction of Tablet Characteristics.
Abstract
The importance of in silico modeling in the pharmaceutical industry is continuously increasing. The aim of the present study was the development of a neural network model for prediction of the postcompressional properties of scored tablets based on the application of existing data sets from our previous studies. Some important process parameters and physicochemical characteristics of the powder mixtures were used as training factors to achieve the best applicability in a wide range of possible compositions. The results demonstrated that, after some pre-processing of the factors, an appropriate prediction p...
Source: AAPS PharmSciTech - February 15, 2013 Category: Drugs & Pharmacology Authors: Sovány T, Papós K, Kása P, Ilič I, Srčič S, Pintye-Hódi K Tags: AAPS PharmSciTech Source Type: research
LCNDG Rapid Review: Brentuximab vedotin for Hodgkin's lymphoma
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
Due to the rarity of the condition and the licensing of brentuximab vedotin, randomised control trials are now unlikely to be conducted for brentuximab vedotin in this indication.
The best available data at this time come from a multinational Phase II study (n=102) that found brentuximab vedotin to be associated with an objective response rate of 75%, with a complete remission seen in 34%. At the time of the analysis, the median duration of response for those in complete remission was 20.5 months and the estimated 12-month su...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Introduction of Best Practice Tariffs: qualitative and quantitative evaluation
Source: Department of Health (DH)
Area: News
An evaluation of the introduction of best practice tariffs (BPT) has been published. The evaluation was commissioned by the Department of Health and the research was carried out by health policy researchers at Nottingham University Business School and the University of Manchester's Institute for Population Health (see Link below for further details).
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Lessons from Europe: provider governance
Source: NHS Confederation
Area: News
A briefing outlining key insights from a 'Lessons from Europe' seminar that examined the impact of recent reforms in hospital governance in Spain and the Netherlands has been published on the NHS Confederation website.
It identifies lessons for NHS managers and policymakers in England on how to approach the challenge of effective provider governance as the present NHS reforms are implemented.
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Review started on rebalancing medicines legislation and statutory professional regulation in pharmacy
Source: General Pharmaceutical Council (GPhC)
Area: News
The UK Chief Pharmaceutical Officers have started a review of the balance between medicines legislation and statutory professional regulation in pharmacy.
See link below for further details
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
GPhC engaging with patients and the public, professionals, and stakeholders on inspection
Source: General Pharmaceutical Council (GPhC)
Area: News
Over the past month, the GPhC has been talking to pharmacy professionals and patients and members of the public about the development of a new approach to inspecting pharmacies.
See link below for more details
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
EMA: Committee for Orphan Medicinal Products - strengthened interactions with patients and international partners
Source: European Medicines Agency (EMA)
Area: News
The European Medicines Agency's Committee for Orphan Medicinal Products will this year begin focusing on integrating the views of patients, expanding international cooperation and collaborating with health-technology-assessment (HTA) bodies for a better understanding of orphan designation.
The Orphan-Medicinal-Product Regulation was introduced in the European Union (EU) to incentivise the development of medicines for rare diseases. Orphan designation can be granted at any stage of the development process to medicines that are intended for diagnosis, prevention or treatm...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Review: Phosphodiesterase inhibitors for erectile dysfunction in men with severe renal disease
Source: Journal of Sexual Medicine
Area: News
Phosphodiesterase inhibitors are generally well tolerated and effective for treating erectile dysfunction (ED), including in patients with significant comorbidity. A review, published in the Journal of Sexual Medicine, examined the safety and efficacy of phosphodiesterase type 5 inhibitors (PDE5) in adult men with erectile dysfunction and severe renal disease or who had received renal transplants.
The authors reviewed published studies of PDE5 inhibitors in patients receiving dialysis or renal transplants. They reported the following findings:
. Sild...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Mesalazine granules once-daily dose provides similar results to twice-daily dose in patients with active, left-sided ulcerative colitis.
The objective of the MOTUS study was to show non-inferiority of once-daily mesalazine versus twice-daily dosing for the induction of remission in active ulcerative colitis. As many patients with ulcerative colitis experience left-sided disease, the aim of the new sub analysis was to assess specifically the efficacy in patients with left-sided ulcerative colitis.
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Retrospective study: Early parenteral nutrition linked to higher death in critically ill children
Source: Reuters Health
Area: News
According to a report in Reuters Health, a retrospective study of 2,069 patients aged one month to 18 years (mean age 5.3 years) who were admitted to a PICU and who received early parenteral nutrition (defined as 25% of goal calories delivered within the first 48 hours of admission) were associated with higher mortality. After adjustment for Paediatric Index of Mortality (PIM)-2 score and centre, children who received early parenteral nutrition were about twice as likely to die as those who did not (odds ratio 2.11, p=0.0002).
Also, median length of stay was significantly longer for th...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
New accreditations from NICE
Source: NICE
Area: News
The National Institute for Health and Clinical Excellence (NICE) has accredited The British Society for Allergy and Clinical Immunology (BSACI) for its processes to produce BSACI guidelines and the College of Occupational Therapists (COT) for its processes to produce Practice Guidelines.
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
NHS Diabetes to become part of the New Improvement Body from April 2013
Source: NHS Diabetes
Area: News
From April 1st a New Improvement Body (NIB) will be established to bring together the wealth of knowledge, expertise and experience of a number of NHS improvement organisations. As a consequence, NHS Diabetes will not exist in its current form after 31 March 2013.
A decision has not yet been taken on whether access to the website and the information and materials on it will be available after 31 March 2013. Users will be sign posted from the site as soon as it is known where electronic versions of the publications and resources can be accessed and obtained from April onwards.
&...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
CADTH rapid review: Antibiotics for the Prevention of Post-Caesarean Section Complications
Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This Canadian review examines the efficacy and safety of antibiotic prophylaxis administered before or after clamping during caesarean sections for the prevention of maternal post-surgical infections.
A total of four systematic reviews and meta-analyses, four randomised controlled trials, and five non-randomised studies were included in this review. Some of the findings were as follows:
. Evidence from one systematic review and one non-randomized study suggested that compared to no antibiotic prophylaxis, antibiotic ...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Horizon Scanning: FDA grants orphan drug status to lenvatinib for thyroid cancer
Source: BioSpace
Area: News
According to a review in Biospace, The U.S FDA has granted orphan drug designation to lenvatinib (E7080) for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer.
Lenvatinib is an investigational small molecule tyrosine kinase inhibitor being studied as an oral agent in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
NHS Choices examine reports of HRT delaying onset of dementia
Source: NHS Choices
Area: News
A number of newspapers have reported that taking hormone replacement therapy (HRT) could delay the onset of Alzheimer's disease for millions of women.
NHS Choices has assessed the study, published in PLOS ONE that involved 63 postmenopausal women who had been taking HRT. The research looked at the relationship between the genetic variant APOE-e4 (known to increase the risk of developing Alzheimer's disease), HRT and telomere length, which is an indicator of cell ageing.
The study found that:
. post-menopausal women who carried APOE-e4 had about six times higher odds of te...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
NHS Choices assessment of press report that women's lung cancer death rates set to rise
Source: NHS Choices
Area: News
NHS Choices has assessed the study, published in Annals of Oncology, which predicted cancer deaths from all forms of cancer across the European Union in 2013, and reported that lung cancer is now the leading cause of cancer-related deaths in British women.
The rise in lung cancer deaths may be caused by:
. the long-term effect of the greater number of women smokers during the 1960s and 70s . the fact that lung cancer remains challenging to treat, as it is often not diagnosed until it is at an advanced stage.
The study also found that between 2009 and 2013, overall death rates...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Company restores some access to multiple sclerosis drug after pressure from neurologists
Source: BMJ
Area: News
Genzyme has restored some access to alemtuzumab that it had previously withdrawn. Genzyme withdrew off-label use of alemtuzumab last year for patients with multiple sclerosis, which caused a large amount of unrest amongst neurologists.
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Horizon scanning: Positive data reported for bavituximab in Stage IV Pancreatic Cancer
Source: BioSpace
Area: News
According to a report in Biospace, an open-label, randomised phase II study of bavituximab in combination with gemcitabine in patients with previously untreated, advanced stage IV pancreatic cancer resulted in more that a doubling of overall response rate (ORR) and a marginal improvement in overall survival (OS) when compared with gemcitabine alone (control arm).
In the trial which enrolled 70 patients, patients treated with a combination of bavituximab and gemcitabine had a 28% tumour response rate as compared to 13% in the control arm. Median OS, the primary endpoint of the trial,...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
RCT: Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in head and neck cancer (PARADIGM- a phase 3 trial).
Source: Lancet Oncology
Area: News
PARADIGM is a multicentre open-label phase 3 study comparing the use of docetaxel, cisplatin, and fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin-based concurrent chemoradiotherapy alone in patients with locally advanced head and neck cancer. One hundred and forty five patients were randomly assigned in a 1:1 ratio to receive either induction chemotherapy with three cycles of TPF followed by concurrent chemoradiotherapy with either docetaxel or carboplatin, or concurrent chemoradiotherapy alone with two cycles of bolus cisplatin. The prim...
Source: NeLM - News - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
LCNDG Rapid Review: Axitinib as an option for second line advanced renal
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
Axitinib (Inlyta®, Pfizer) is an orally administered multi-targeted kinase receptor inhibitor that has been licensed in the EU for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. There are currently no treatments approved by NICE for use in people with advanced RCC who have failed to respond to prior systemic therapy. However, sunitinib and everolimus are occasionally prescribed as second-line treatments through the Cancer Drugs Fund; and are also suggest...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
LCNDG Rapid Review: Bendamustine for relapsed follicular lymphoma refractory to rituximab
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
The manufacturer of bendamustine (Napp Pharmaceuticals) was invited to submit evidence for a NICE single technology appraisal (STA) in May 2010. In June 2010, the manufacturer informed NICE that it would not be making an evidence submission because it was unable to identify comparative clinical evidence suitable for a NICE appraisal in people with rituximab refractory disease. The manufacturer indicated that further research was ongoing but data would not be available in a time frame that would allow NICE to produce timely guidance. NICE ther...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
Brentuximab vedotin for Hodgkin's lymphoma
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
Due to the rarity of the condition and the licensing of brentuximab vedotin, randomised control trials are now unlikely to be conducted for brentuximab vedotin in this indication.
The best available data at this time come from a multinational Phase II study (n=102) that found brentuximab vedotin to be associated with an objective response rate of 75%, with a complete remission seen in 34%. At the time of the analysis, the median duration of response for those in complete remission was 20.5 months and the estimated 12-month su...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
LCNDG Rapid Review: Lenalidomide for 1st relapse multiple myeloma after bortezomib
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
NICE recommends the use of lenalidomide for relapsed multiple myeloma only in those who have received two or more prior therapies.
The best available evidence to support the use of lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma comes from two phase III studies (MM-009 and MM-010). Both trials compared lenalidomide/dexamethasone to dexamethasone alone, and both trials used a primary endpoint of time to disease progression. There was only a limited number of patients in the two phase III s...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
LCNDG Rapid Review: Tegafur, gimeracil, and oteracil (known as S1)for first-line palliative treatment of advanced gastric cancer
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
The evidence to support tegafur/gimeracil/oteracil plus cisplatin for this indication derives from one pivotal phase III multicentre, randomised, open-label study to compare overall survival (OS) for cisplatin plus tegafur/gimeracil/oteracil (CS) with cisplatin plus 5-fluorouracil iv (CF) in adult patients with advanced gastric cancer, previously untreated with chemotherapy (FLAGS study). It is important to note that the comparator used in the FLAGS study (CF) is not relevant for UK practice, where patients would normally receive EOX or ECX. ...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
CARE ONE CREAMY COCONUT (Ethyl Alcohol) Liquid [AMERICAN SALES COMPANY]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
CONRX EXTRA STRENGTH (Acetaminophen) Tablet [Eagle Distributors,Inc.]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
CONRX PAIN RELIEVER (Acetaminophen, Aspirin, And Caffeine) Tablet [Eagle Distributors,Inc.]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
COMPLEXION CORRECTOR SPF20 (Titanium Dioxide And Zinc Oxide) Cream [Omorovicza Kozmetikai Kft.]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
SYALLGEN (Penicillium Glabrum) Tablet [Syntrion GmbH]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
DOUBLE ANTIBIOTIC (Bacitracin Zinc And Polymyxin B Sulfate) Ointment [E. Fougera Co. A Division Of Fougera Pharmaceuticals Inc.]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
GABAPENTINcapsule [REMEDYREPACK INC. ]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
SYRESP (Aspergillus Niger Var. Niger) Tablet [Syntrion GmbH]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
CONRX ALLERGY (Diphenhydramine Hydrochloride) Tablet [Eagle Distributors,Inc.]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
SKIN SO SOFT BUG GUARD PLUS IR3535 COOL N FABULOUS DISAPPEARING COLOR INSECT REPELLENT SUNSCREEN (Octinoxate, Oxybenzone, Octisalate) Lotion [Avon Products, Inc]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
DIPROLENE (Betamethasone Dipropionate) Lotion [Merck Sharp Dohme Corp.]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
SOLUTIONS NECK AND CHEST PERFECTOR (Octinoxate, Oxybenzone, Octisalate, Avobenzone ) Cream [Avon Products, Inc.]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
ANTISEPTIC (Benzalkonium Chloride) Liquid [MAC Medical Supply Company, Inc.]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
LEVOTHYROXINE SODIUMtablet [REMEDYREPACK INC. ]
Updated Date: Feb 15, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
